Business Context and Reporting Period
Artele Biosciences, Inc. filed a Form 8-K Current Report on January 18, 2018, regarding an event that occurred on the same date. The company is incorporated in Nevada and is based in La Jolla, California.
Key Financial Metrics
This filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on the terms of a new contractual agreement.
Material Changes
The primary material change is the entry into an Exclusive License Agreement with The Research Foundation for the State University of New York (the "Foundation"). Key terms include:
- Scope: Exclusive worldwide license to develop, manufacture, and sell patent products in all fields, including human therapeutics.
- Upfront and Maintenance Fees: The company must pay an upfront fee and annual license maintenance fees starting on the first anniversary of the effective date.
- Royalties: Obligations to pay royalties on net sales, with provisions for reductions in certain cases.
- Annual Minimum Royalty: Required beginning in the first calendar year of commercial sales, credited against total royalties due.
- Milestone Payments: Payments are triggered by specific events, including:
- Lead candidate selection or the second anniversary of the agreement (whichever comes first).
- Initiation of Phase II and Phase III clinical trials for the first indication of each active pharmaceutical ingredient.
- FDA or EMA regulatory approval for the first indication.
- FDA or EMA approval for second and subsequent indications.
- First time annual net sales exceeding $100,000,000 and $500,000,000.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the obligations inherent in the license agreement. The agreement term continues until terminated. The full text of the agreement is noted as an exhibit to be filed in a future Form 10-Q.
Investor Verification Checklist
- Verify the specific amount of the upfront fee and annual maintenance fees, as these values are not disclosed in this summary.
- Confirm the royalty percentage rates and the specific conditions for royalty reductions.
- Review the full text of the Exclusive License Agreement when filed as an exhibit to the Form 10-Q for complete legal terms.
- Assess the company's current cash position to determine its ability to fund the upfront fee and future milestone payments.